„Aus 1 mach 2“: die neuen Lymphomklassifikationen der WHO und der ICC

Klassifikationen sind ein unabdingbarer Bestandteil der Tumordiagnostik – nur durch eine adäquate Einordnung der einzelnen Läsionen ist auch eine entsprechend angepasste Therapie möglich. Aktuell liegen jedoch 2 Klassifikationen vor: die 5. Version der WHO-Klassifikation und die internationale Konsensusklassifikation. Dieser Übersichtsartikel stellt die überwiegenden Gemeinsamkeiten und die wenigen, aber nicht unerheblichen Unterschiede der beiden Klassifikationen vor.

Schlüsselwörter

Lymphom - WHO-Klassifikation - ICC-Klassifikation

Publication History

Article published online:
02 December 2024

• Literatur

• 1 Arber DA, Haeerjian RP, Orazi a. et al. Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. Am J Hematol 2022; 97 (05) 514-518
• 2 Alaggio R, Amador C, Anagnostopoulos I. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36 (07) 1720-1748
• 3 Campo E, Jaffe ES, Cook JR. et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140 (11) 1229-1253
• 4 Menter T, Quintanilla-Martinez L. CD23 positive, BCL2 rearrangement-negative germinal centre lymphomas. Pathologie (Heidelb) 2023; 44 (Suppl. 03) 160-163
• 5 de Leval L, Alizadeh AA, Bergsagel PL. et al. Genomic profiling for clinical decision making in lymphoid neoplasms. Blood 2022; 140 (21) 2193-2227
• 6 Berentsen S, Barcellini W, D'Sa S. et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood 2020; 136 (04) 480-488
• 7 Hoster E, Rosenwald A, Berger F. et al. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. J Clin Oncol 2016; 34 (12) 1386-1394
• 8 Hans CP, Weisenburger DD, Greiner TC. et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103 (01) 275-882
• 9 Runge HFP, Lacy S, Barrans S. et al. Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL). Br J Haematol 2021; 192 (01) 216-220
• 10 Wright GW, Huang DW, Phelan JD. et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 2020; 37 (04) 551-568 e14
• 11 Ivanova VS, Vela V, Dirnhofer S. et al. Molecular characterization and genetic subclassification comparison of diffuse large B-cell lymphoma (DLBCL) – real-life experience with 74 cases. Pathobiology 2023; 04: 91
• 12 Künstner A, Witte HM, Riedl J. et al. Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing. Haematologica 2022; 107 (08) 1850-1863
• 13 King RL, Goodlad JR, Calaminici M. et al. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. Virchows Arch 2020; 476 (05) 647-665
• 14 Di Napoli A, Soma L, Quintanilla-Marquez L. et al. Cavity-based lymphomas: challenges and novel concepts. A report of the 2022 EA4HP/SH lymphoma workshop. Virchows Arch 2023; 483 (03) 299-316
• 15 Wagener R, Seufert J, Raimondi F. et al. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood 2019; 133 (09) 962-966
• 16 Rodriguez M, Alonso-Alonso R, Tomás-Roca L. et al. Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers. Blood Adv 2021; 5 (24) 5588-5598
• 17 Hartmann S, Eichenauer DA. Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma. Pathology 2020; 52 (01) 142-153